The US could soon get a new private uranium enrichment facility.
Posts from this topic will be added to your daily email digest and your homepage feed. See All AI
Posts from this topic will be added to your daily email digest and your homepage feed. See All Climate
Posts from this topic will be added to your daily email digest and your homepage feed. See All Energy
Posts from this topic will be added to your daily email digest and your homepage feed. See All Environment
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Science
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
17 minutes ago
- Fox News
AI tech detects hidden heart disease doctors often miss
You might think heart disease comes with warning signs. But some of the deadliest types, like structural heart disease (SHD), creep in silently. No chest pain. No shortness of breath. Nothing until it's too late. Now, a new artificial intelligence tool called EchoNext is changing the game. It can flag hidden heart problems that even trained cardiologists miss just by analyzing a standard ECG. That's right. A routine, five-minute heart test you've probably already had could now unlock life-saving information if AI is watching. Sign up for my FREE CyberGuy Report Get my best tech tips, urgent security alerts and exclusive deals delivered straight to your inbox. Plus, you'll get instant access to my Ultimate Scam Survival Guide — free when you join my CAN YOUR APPLE WATCH DETECT PREGNANCY? What is structural heart disease, and why is it so dangerous? SHD refers to defects in the heart's walls, valves or chambers. Some are present at birth. Others develop slowly over time. Either way, they often go unnoticed until something major happens, like a heart attack or stroke. That's why experts sometimes call SHD the "hidden" heart disease. Here's the problem. Even the ECGs doctors routinely use to spot heart issues often can't detect SHD on their own. And that's where EchoNext comes in. WHAT IS ARTIFICIAL INTELLIGENCE (AI)? EchoNext: The AI that knows when to dig deeper EchoNext was created by researchers at Columbia University and NewYork-Presbyterian. The tool was trained on over 1.2 million ECG and echocardiogram pairs from more than 230,000 patients. Its job? Figure out when a patient's ECG suggests a deeper look is needed, specifically, an echocardiogram, the ultrasound that gives a detailed view of heart structure. "EchoNext basically uses the cheaper test to figure out who needs the more expensive one," explained Dr. Pierre Elias, who led the study. And the results? Stunning. EchoNext outperformed human cardiologists In tests, EchoNext correctly flagged 77% of structural heart disease cases from ECGs. Cardiologists? Just 64%. Even more impressive, when tested on nearly 85,000 people, EchoNext identified over 7,500 at high risk for undiagnosed SHD. A year later, researchers found that 73% of those who followed up with echocardiograms were indeed diagnosed with SHD, a rate far above average. These groundbreaking results were published in Nature, one of the world's most respected scientific journals. That's not just a better test. That's a potential lifesaver. GET FOX BUSINESS ON THE GO BY CLICKING HERE Why this matters now more than ever Millions walk around every day with SHD and have no idea. They skip heart screenings because nothing feels wrong. Even when they do get an ECG, subtle warning signs can slip by unnoticed. EchoNext doesn't miss them. And it doesn't get tired or distracted. This isn't about replacing doctors. Iit's about giving them a powerful new tool to catch what humans alone can't. What this means for you You don't need to wait for symptoms to take your heart health seriously. If you've ever had an ECG, or you're getting one soon, AI could now help spot hidden risks your doctor might miss. Tools like EchoNext make it easier to catch heart problems early, even if you feel fine. This means fewer surprises, fewer missed diagnoses and a better shot at treatment before it's too late. It's not about replacing doctors. It's about giving them, and you, a better shot at catching problems early. Ask your doctor if AI tools are being used to review your heart tests. You deserve every advantage. Right now, EchoNext is being used in research settings, but tools like it are quickly moving toward wider use in hospitals and clinics. CLICK HERE TO GET THE FOX NEWS APP Kurt's key takeaways AI is no longer the future of medicine. It's happening now. EchoNext proves that machine learning can radically improve how we detect silent killers like SHD. If a simple ECG plus AI could save thousands of lives, what are we waiting for? Would you trust a machine to catch what your cardiologist might overlook? Let us know by writing us at Sign up for my FREE CyberGuy Report Get my best tech tips, urgent security alerts and exclusive deals delivered straight to your inbox. Plus, you'll get instant access to my Ultimate Scam Survival Guide — free when you join my Copyright 2025 All rights reserved.
Yahoo
2 hours ago
- Yahoo
Ultromics Lands $55M Series C to Tackle Undiagnosed Heart Failure at Scale
AI heart failure diagnostics innovator makes it possible to catch deadly heart failure earlier by analyzing the most common heart scan in the world and proactively alerting clinicians FDA-cleared, reimbursed by Medicare, and live in top U.S. hospitals, Ultromics is now scaling nationwide to make early heart failure detection part of routine cardiac care, wherever patients get an echo Ultromics is trained on one of the largest real-world echo datasets globally and validated across 25 peer-reviewed studies, helping close one of medicine's most dangerous diagnostic gaps, where up to 64% of heart failure cases still go undetected OXFORD, England, July 31, 2025 /PRNewswire/ -- Ultromics, a pioneer in AI-driven cardiology solutions, today announced it has raised $55 million in Series C financing. The round was co-led by L&G, Allegis Capital and Lightrock, with continued support from Oxford Science Enterprises, GV, Blue Venture Fund and Oxford University. Major U.S. health systems, including UChicago Medicine's venture investment vehicle, UCM Ventures, and UPMC Enterprises also participated in the round. Built on years of clinical study and hundreds of thousands of echo scans, Ultromics offers the first FDA-cleared, Medicare-reimbursed AI technology to help clinicians detect HFpEF and cardiac amyloidosis, two of the most elusive forms of heart failure. The company is now expanding across the U.S. to bring that capability to the hospitals and echo labs that see the highest volume of at-risk patients, aiming to make AI-enhanced diagnostics a default step in the cardiac workup. Ultromics is also expanding its pipeline to include additional cardiac conditions, new distribution channels and deeper partnerships with health systems and clinical leaders. It's a critical moment for cardiovascular care. Heart failure is rising, costs are mounting and millions of patients are still going undiagnosed, especially those with harder-to-detect forms like HFpEF and cardiac amyloidosis. In the U.S. alone, heart failure drives over $30 billion in annual healthcare costs, a number projected to exceed $70 billion by 2030. Clinicians often rely on subjective interpretation of echocardiograms, leading to missed or delayed diagnoses even when patients are actively seeking care. In fact, up to 64% of HFpEF cases go undiagnosed, and cardiac amyloidosis is frequently mistaken for more common forms of heart disease, leaving patients untreated until symptoms worsen or irreversible damage occurs. Ultromics addresses this diagnostic blind spot by using AI to extract hidden disease signals from standard echocardiograms, enabling earlier, more accurate detection of complex heart conditions—without requiring new hardware or disrupting clinical workflows. Its FDA-cleared EchoGo® platform supports diagnosis of HFpEF and cardiac amyloidosis. Trained and validated on one of the largest real-world echo datasets globally, EchoGo® generates real-time probability scores to help cardiologists identify high-risk patients earlier than traditional methods. EchoGo® is fully reimbursed under Medicare, making it scalable across hospitals, clinics, and health systems nationwide. "The reality is, hospitals already have the data, they just haven't had the tools to extract the more subtle diagnostic signals from it. By analyzing routine echocardiograms with AI, we're helping clinicians identify high-risk patients earlier, enabling intervention before disease progresses," said Ross Upton, PhD, CEO and Founder, Ultromics. "We've spent years building our platform to fit into clinical workflows, with no extra hardware and no new friction, and this funding helps us scale that across the U.S. at a moment when health systems are actively looking to combat the growing heart failure crisis." Ultromics has already analyzed more than 430,000 echocardiograms to date. In clinical studies, EchoGo® improved the detection of HFpEF by 73.6% when compared with standard clinical risk scores. The company's latest diagnostic model for cardiac amyloidosis, validated in a global study of 18 institutions and published in the European Heart Journal, outperformed current clinical risk scores while distinguishing disease from similar conditions. "Ultromics has established itself as an early-mover in the large and underserved cardiovascular disease market, having developed one of the first commercially available AI-powered diagnostic echocardiogram technologies," said Alastair Stewart, Head of Investments, Venture Capital, at L&G. "This successful Series C round is a testament to the massive opportunity for cutting-edge technology to transform how clinicians can detect and treat serious cardiovascular diseases that impact millions of people every year." With growing adoption and partnerships across flagship institutions, including UChicago Medicine, University Hospitals Cleveland, Northwestern, and Mayo Clinic, Ultromics is building regional clusters of clinical and commercial traction, particularly in high-prevalence regions like the Midwest. Its platform is helping hospitals reduce unnecessary tests, streamline workflows and initiate treatment earlier so it's more effective and less expensive. "Heart failure and cardiac amyloidosis impact millions of lives and strain healthcare systems, despite new approaches that have the potential to significantly improve patient outcomes. There is a critical need for scalable solutions that enable earlier, more accurate diagnosis and elevate the standard of care," said Umur Hursever, Partner at Lightrock. "Ultromics' AI-driven technology is already making a real-world impact, improving diagnostic accuracy, supporting clinical decisions, and expanding access to specialist care. The Lightrock team is delighted to support Ultromics' mission and growing impact." Ultromics has rapidly expanded its platform capabilities and U.S. market presence during the past year. In late 2024, the company received FDA Breakthrough Device clearance for EchoGo® Amyloidosis, followed in 2025 by the launch of EchoGo® Score, a new feature that adds AI-driven probability scoring to EchoGo® Heart Failure, helping clinicians detect HFpEF with greater nuance. These clinical advances are now supported by Medicare reimbursement for both outpatient and inpatient use, strengthening Ultromics' foundation for scaled adoption across U.S. hospitals. "There's a long-standing blind spot in cardiology where millions of patients with treatable heart failure are missed because their symptoms are subtle and echo images are hard to interpret," said Victor Westerlind, Managing Director at Allegis Capital. "What's exciting about Ultromics is how they're closing that gap. Their platform brings AI and cardiology together in a way that makes it easier for physicians to identify high-risk patients earlier. When paired with the latest treatment advances, it's a diagnostic win that will help save lives." About Ultromics Founded out of the University of Oxford, Ultromics is redefining cardiovascular care with FDA-cleared, AI-powered tools that enhance echocardiographic diagnosis. Built in partnership with the NHS and Mayo Clinic, its EchoGo® platform helps clinicians detect complex heart diseases earlier and more accurately—using nothing more than a standard ultrasound scan. Ultromics is backed by leading investors and U.S. healthcare systems and is on a mission to transform how heart disease is diagnosed and treated. For more, visit About Lightrock Lightrock is a global investment platform committed to building a sustainable future. Operating across private and public markets, Lightrock manages over $5.5 billion in assets and invests in Europe, North America, Latin America, Asia, and Africa. Lightrock is a certified B Corp with a dedicated team of over 130 professionals working across a network of six offices For more information, visit About L&G Established in 1836, L&G is one of the UK's leading financial services groups and a major global investor, with £1.1 trillion in total assets under management (as at FY24) of which c. 44% (c. £0.5 trillion) is international. We have a highly synergistic business model, which continues to drive strong returns. We are a leading player in Institutional Retirement, in Retail Savings and Protection, and in Asset Management through both public and private markets. Across the Group, we are committed to responsible investing and dedicated to serving the long-term savings and investment needs of customers and society. About Allegis Capital Allegis Capital is an early-stage venture capital firm partnering with companies that enable digital transformation across the enterprise. The firm supports founders with hands-on guidance, operational expertise, and access to a global network of industry leaders. With a long track record of building market-defining businesses, Allegis backs the teams and platforms reshaping how work gets done. Headquartered in Palo Alto, California, Allegis has been investing in enterprise innovation for over two decades. For more information, visit Photo - - View original content to download multimedia: SOURCE Ultromics Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Microsoft Releases List of Jobs Most and Least Likely to Be Replaced by AI
Researchers at Microsoft tried to determine which precise jobs are most and least likely to be replaced by generative AI — and the results are bad news for anyone currently enjoying the perks of a cushy desk job. As detailed in a yet-to-be-peer-reviewed paper, the Microsoft team analyzed a "dataset of 200k anonymized and privacy-scrubbed conversations between users and Microsoft Bing Copilot," and found that the occupations most likely to be made obsolete by the tech involve "providing information and assistance, writing, teaching, and advising." The team used the data to come up with an "AI applicability score," an effort to quantify just how vulnerable each given occupation is, taking into consideration how often AI is already being used there and how successful those efforts have been. According to the analysis, jobs most likely to be replaced include translators, historians, sales reps, writers, authors, and customer service reps. Jobs that are the safest from AI automation, in contrast, include heavy machinery and motorboat operators, housekeepers, roofers, massage therapists, and dishwashers. In other words, the sweeping takeaway was that lower-paying and manual labor-focused occupations are far less likely to be automated than occupations that suit the expertise of large language model-based AI chatbots. However, we should take the results with a healthy grain of salt. For one, we should consider that Microsoft employees are incentivized to paint the technology in the best light by the company's massive investments in the space, which could lead to overstating generative AI's capabilities. The researchers also warn that "our data do not indicate that AI is performing all of the work activities of any one occupation," meaning that for many gigs, AI won't be able to take over 100 percent of tasks. Then there's the fact that "different people use different LLMs for different purposes" and that the nature of many jobs isn't perfectly represented in the data. That could explain why certain jobs, such as historians, authors, and political scientists, ended up with some of the highest AI applicability scores, despite greatly relying on human intuition and expertise, and having to work with incomplete or contradictory documentation. That's not to mention the tech's propensity to hallucinate made-up factual claims. That's an inconvenient reality that hangs over the whole paper and the AI industry itself: even if the tech does end up replacing a lot of human jobs, it's likely it will do so by providing an inferior service that we'll just have to learn to live with. The team also cautioned — although again, remember Microsoft's economic interests — that replacing jobs doesn't necessarily mean that employment or wages in a sector will decline. "Our study explores which job categories can productively use AI chatbots," said Kiran Tomlinson, a Senior Researcher at Microsoft who worked on the research. "It introduces an AI applicability score that measures the overlap between AI capabilities and job tasks, highlighting where AI might change how work is done, not take away or replace jobs." "Our research shows that AI supports many tasks, particularly those involving research, writing, and communication, but does not indicate it can fully perform any single occupation," he continued. "As AI adoption accelerates, it's important that we continue to study and better understand its societal and economic impact." The team also cautioned that "our data do not include the downstream business impacts of new technology, which are very hard to predict and often counterintuitive," in their paper. "Take the example of ATMs, which automated a core task of bank tellers, but led to an increase in the number of bank teller jobs as banks opened more branches at lower costs and tellers focused on more valuable relationship-building rather than processing deposits and withdrawals." It's a common refrain among tech companies that generative AI will lead to the creation of new types of jobs, a convenient conclusion that neatly counters ongoing narratives of imminent job losses. But not everybody in the industry is trying to soften the blow. Earlier this month, OpenAI CEO Sam Altman warned that entire job categories could be wiped out by AI, with "some areas" in the job market, such as customer support roles, being "just like totally, totally gone." And Elijah Clark, a CEO who advises other company leaders on how to make use of AI, recently told Gizmodo that "CEOs are extremely excited about the opportunities that AI brings." "As a CEO myself, I can tell you, I'm extremely excited about it," he added. "I've laid off employees myself because of AI." In short, while it's an interesting glimpse into how users are making use of AI chatbots such as Microsoft's Bing Copilot, it's difficult to get an accurate picture of what the job market will look like in the years to come. "Exactly which new jobs emerge, and how old ones are reconstituted, is an important future research direction in the AI age," the researchers wrote. "At the same time, the technology itself will continue to evolve; our measurement of AI applicability is only a snapshot in time." "Modernizing our understanding of workplace activities will be crucial as generative AI continues to change how work is done," they concluded. More on AI automation: Engineer: With AI, "Anybody Whose Job Is Done on a Computer All Day Is Over... It's Just a Matter of Time"
